Delos Capital

Allecra Therapeutics reported that EXBLIFEP was superior to piperacillin-tazobactam in clinical cure and microbiological eradication at test of cure, with a comparable safety profile.

Antios Therapeutics, Inc. initiated its first-in-human Phase I clinical trial for ATI-2173, an orally administered, liver-targeted small molecule for hepatitis B.

Clover Biopharmaceuticals entered a research collaboration with GSK on its COVID-19 S-Trimer vaccine candidate; GSK will provide its pandemic adjuvant system for evaluation.

Clover Biopharmaceuticals announced development of a recombinant subunit vaccine for 2019-nCoV, the newly identified coronavirus believed to have originated in Wuhan, China.

Agnes joined Delos Capital in 2018 and is financial controller in Hong Kong, overseeing accounting, tax, reporting, and compliance. She previously spent eight years at Bank of America Merrill Lynch and nearly 10 years at Ernst & Young.

Andrea joined Delos Capital in 2022 and is the Executive Assistant for the Hong Kong office. Prior to joining Delos, Andrea was a secretary in the Corporate Legal Department at Nan Fung Group. She received a Bachelors in English for Professional Communications at City University of Hong Kong.

Carrie joined Delos in June 2024 and manages operations for its Boston office. Carrie has over 15 years of operations experience, most recently as director of finance and operations at a Santa Monica-based event technology company.

Lee joined Delos Capital as a Managing Director in 2024. He is committed to helping advance meaningful new medicines for patients.

Delos Capital has life sciences investment and partnership opportunities, with contacts in Cambridge, MA, and Hong Kong.

Delos Capital invests in life science, biotech, and medtech companies transforming bold ideas into medical breakthroughs.

Delos Capital's privacy policy describes how it collects, uses, and safeguards personal information.